An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Universitair Ziekenhuis Antwerpen, Edegem

Children's Hospital of Philadelphia, Philadelphia

UNC Children's Research Institute, Chapel Hill

Cincinnati Children's Hospital Medical Center, Cincinnati

The University of Texas Medical School at Houston, Houston

UCSF Benioff Children's Hospital Oakland, Oakland

Sanatorio Mater Dei, Buenos Aires

UZ Brussel, Jette

University of Alberta - Faculty of Medicine & Dentistry, Edmonton

Hopital Jeanne De Flandre - Metabolic Diseases Unit, Lille

Universitätsklinikum Hamburg-Eppendorf, Hamburg

SpinCS GmbH, Höchheim

Azienda Sanitaria Universitaria Friuli Centrale - PO Universitario Santa Maria della Misericordia, Udine

Hospit U. Vall d'Hebron - PPDS, Barcelona

Drottning Silvias Barn Och Ungdomssjukhus, Gothenburg

University Medical Faculty Balcali Hospital, Adana

Gazi Universitesi Tip Fakultes, Ankara

Hospital for Sick Children, Toronto

McGill University Health Center, Montreal

Vseobecna Fakultni Nemocnice V Praze, Prague

Erasmus Medical Center - Sophia Children's Hospital, Rotterdam